IDEAYA Initiates Phase 1 Trial for PRMT5 Inhibitor, Deprioritizes Trodelvy Combination

Event summary

  • IDEAYA Biosciences initiated a Phase 1 clinical trial for IDE892, a PRMT5 inhibitor, targeting MTAP-deleted solid tumors including NSCLC and PDAC.
  • The trial will evaluate IDE892 as a monotherapy and in combination with IDE397 (MAT2A inhibitor), with combination studies planned to begin mid-2026.
  • IDEAYA is deprioritizing combination activities with Trodelvy and Gilead, citing a strategic focus on its MTAP-deleted and CDKN2A pipeline.
  • The company expects to nominate a first-in-class CDKN2A development candidate in H2 2026 and initiate an IND in H1 2027.
  • IDE892 demonstrates ~1,400-fold selective binding to MTA-PRMT5 and single-digit nanomolar potency in MTAP-deleted cell lines.

The big picture

IDEAYA's decision to deprioritize Trodelvy reflects a broader trend in precision oncology towards greater reliance on internally developed assets and a focus on synergistic combinations. The company's strategy hinges on exploiting synthetic lethal vulnerabilities in MTAP-deleted tumors, a relatively rare but underserved patient population. Success will depend on demonstrating clinical efficacy with its pipeline and navigating the complexities of biomarker-driven patient selection.

What we're watching

Clinical Efficacy
The Phase 1 trial results will be critical in determining IDE892's therapeutic window and potential for clinical benefit as a monotherapy and in combination with IDE397, particularly given the limited treatment options for MTAP-deleted tumors.
Pipeline Focus
The deprioritization of Trodelvy combination studies signals a shift in IDEAYA's strategy; the success of its internally developed pipeline, especially the CDKN2A program, will be key to justifying this redirection.
Regulatory Pathway
The speed with which IDEAYA can advance its CDKN2A program to IND submission, and subsequently clinical trials, will depend on preclinical data and could influence investor sentiment regarding the company's long-term prospects.

Related topics

Pharmaceuticals Precision Medicine Oncology